Similar to targeting CD19 in B-ALL and B-cell lymphomas by chimeric antigen receptor (CAR)-T cells and CD19-directed bispecific T-cell engager (bTCE) therapy, or CD38 in multiple myeloma, these are all antigens that are also expressed by non-malignant haematopoietic progenitor cells (see review of Assi et al). 57. This evidence concerns the gene CD19 and plasma cell myeloma.